Shares of MacroGenics went stratospheric Wednesday following the release of data from a pivotal Phase III study of the company’s lead drug candidate in breast cancer that beat many investors’ expectations.
{iframe}https://medcitynews.com/2019/02/macrogenics-stock-price-more-than-doubles-on-successful-breast-cancer-study/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=69686183&_hsenc=p2ANqtz-_64lptSEJmSj5heloHSYjN0T5DbGRbmckQwaJSs_K-ecegLV4tkcFzzYz5DiFVBxFceKnUlINN_75UXhHPgp7D651OWw&_hsmi=69686183{/iframe}